Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine vs escitalopram in severe generalized anxiety disorder (non-depressed outpatients)
2012-003699-37Phase 3Completed
- Sponsor
- Servier
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in generalized anxiety disorder (GAD) (2 arms), sponsored by Servier. Primary endpoint: HAM-A total score. Started Nov 2012; status: completed.
02
Drugs
agomelatine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2012-003699-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003699-37.